Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF530 vs Betaferon in Healthy Volunteers
NCT02474134Phase 1Completed
- Sponsor
- Pfenex Inc.
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF530 in multiple sclerosis (MS) (2 arms), sponsored by Pfenex Inc. Primary endpoint: Adverse event (AE) and serious adverse event (SAE) incidence at 28 Days. Started Mar 2015; status: completed.
02
Drugs
PF530
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02474134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474134.